Tag: multiple sclerosis

1. In recent years, the risk of persistent disability has been significantly reduced in patients with pediatric-onset multiple sclerosis (POMS), likely owing to availability of new disease-modifying therapies (DMTs) and changes to therapeutic paradigms over time. 2. Further research in therapeutic efficacy and management in the pediatric population is needed...

1. Ponesimod was superior to teriflunomide for relapsing multiple sclerosis, in terms of reducing relapse rates, unique active lesions on MRI, and fatigue symptoms. Evidence Rating Level: 1 (Excellent) Multiple sclerosis (MS) is an autoimmune, chronic disease where demyelination and loss of axons manifest in relapses and recurrent attacks, leading to...

1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple sclerosis compared to those treated with teriflunomide 2. The ofatumumab treatment group had less disability worsening, improved number of enhancing lesions per MRI scans, and lower serum neurofilament light chains...

1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple sclerosis compared to those treated with teriflunomide 2. The ofatumumab treatment group had less disability worsening, improved number of enhancing lesions per MRI scans, and lower serum neurofilament light chains...

The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study 1. PPI use may be associated with an increased mortality risk in patients who have received kidney transplants. Evidence Rating Level: 1 (Excellent) Proton-pump inhibitors (PPIs) are commonly prescribed to kidney transplant recipients (KTRs) to protect...

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) 1. No association was found between angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use and test-positivity for COVID-19. Evidence Rating Level: 2 (Good) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the...

Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-Being, and Health Care Use: The Care Ecosystem Randomized Clinical Trial 1. A model of dementia care management implemented through telephone and internet was shown to be more effective in improving health outcomes in patients with...

1. Increased serum neurofilament light chain levels, a biomarker for neuroaxonal damage, may be associated with a prodromal or subclinical phase in the setting of multiple sclerosis (MS). Evidence Rating Level: 3 (Average) While most patients affected by multiple sclerosis (MS) experience initial symptoms in early adulthood, there is increasing evidence...

Multiple sclerosis (MS) is a progressive, degenerative disease that damages myelin sheaths in the central nervous system. The RADIANCE phase 2 study previously established that ozanimod, a sphingosine 1-phosphate receptor modulator, demonstrates greater efficacy on MRI measures in patients with relapsing MS. SUNBEAM, a randomized, double-dummy, double-blind, active-controlled phase...

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial 1. A shortened course of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer was associated with decreased peripheral sensory neuropathy without compromising effectiveness. Evidence Rating Level:...